HC Wainwright reiterated their buy rating on shares of Foamix Pharmaceuticals (NASDAQ:FOMX) in a report published on Wednesday, Marketbeat.com reports. HC Wainwright currently has a $14.00 price target on the specialty pharmaceutical company’s stock, up from their previous price target of $12.00.

A number of other research analysts have also commented on FOMX. ValuEngine upgraded shares of Foamix Pharmaceuticals from a hold rating to a buy rating in a research note on Monday, July 2nd. Zacks Investment Research upgraded shares of Foamix Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, July 11th.

Shares of NASDAQ:FOMX opened at $6.18 on Wednesday. Foamix Pharmaceuticals has a 52 week low of $4.40 and a 52 week high of $7.60.

Foamix Pharmaceuticals (NASDAQ:FOMX) last posted its quarterly earnings data on Wednesday, August 8th. The specialty pharmaceutical company reported ($0.46) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.10. Foamix Pharmaceuticals had a negative net margin of 2,085.71% and a negative return on equity of 131.84%. The business had revenue of $0.96 million for the quarter, compared to analyst estimates of $1.10 million. analysts forecast that Foamix Pharmaceuticals will post -1.69 EPS for the current year.

In other Foamix Pharmaceuticals news, CEO David Domzalski sold 8,238 shares of Foamix Pharmaceuticals stock in a transaction that occurred on Wednesday, August 8th. The shares were sold at an average price of $5.68, for a total value of $46,791.84. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold 11,764 shares of company stock worth $66,387 in the last quarter. Company insiders own 3.30% of the company’s stock.

A number of institutional investors have recently bought and sold shares of FOMX. Eversept Partners LLC acquired a new position in Foamix Pharmaceuticals in the first quarter worth approximately $551,000. A.R.T. Advisors LLC acquired a new position in Foamix Pharmaceuticals in the first quarter worth approximately $104,000. Sofinnova Ventures Inc acquired a new position in Foamix Pharmaceuticals in the first quarter worth approximately $369,000. Millennium Management LLC grew its position in Foamix Pharmaceuticals by 2.6% in the first quarter. Millennium Management LLC now owns 763,296 shares of the specialty pharmaceutical company’s stock worth $3,916,000 after buying an additional 19,628 shares during the last quarter. Finally, Handelsbanken Fonder AB grew its position in Foamix Pharmaceuticals by 35.0% in the first quarter. Handelsbanken Fonder AB now owns 364,500 shares of the specialty pharmaceutical company’s stock worth $1,870,000 after buying an additional 94,500 shares during the last quarter. Hedge funds and other institutional investors own 58.48% of the company’s stock.

About Foamix Pharmaceuticals

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus.

Read More: Exchange-Traded Funds (ETFs)

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.